HZ97ZZZ
Pharmacotherapy Bupropion to None with None, None Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | H Substance Abuse Treatment |
| Body System | Z None |
| Operation | 9 Pharmacotherapy |
| Body Part | 7 Bupropion |
| Approach | Z None |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
The use of replacement medications for the treatment of addiction
Procedure Overview
Pharmacotherapy in this context is the use of replacement medications, such as methadone, buprenorphine, or naltrexone, to treat substance addiction. These medications work by reducing withdrawal symptoms and cravings or by blunting the euphoric effects of the substance being misused, which helps stabilize patients enough to engage in counseling and rebuild daily functioning. It is one of the most evidence-supported approaches to treating opioid and alcohol use disorders and is frequently paired with behavioral therapy.
The medication is typically dispensed in a licensed opioid treatment program, outpatient clinic, or inpatient facility, often under supervised or observed conditions, particularly during the early stabilization phase. Over time, patients may transition to less frequent visits or take-home doses as their treatment stabilizes. This root operation captures the administration event itself rather than the broader oversight of the regimen, distinguishing it from ongoing monitoring activities that occur separately.
Anatomy & Axis Detail
Bupropion
Bupropion is an atypical antidepressant that inhibits norepinephrine and dopamine reuptake, and within substance abuse treatment it is used chiefly to support smoking cessation by reducing nicotine craving and withdrawal irritability, with off-label use also seen in stimulant use disorder management. Unlike nicotine replacement products, it contains no nicotine and works through a distinct neurochemical mechanism, which is why it is coded separately from nicotine replacement therapy. Documentation typically reflects its administration as part of a structured cessation or dual-diagnosis treatment plan, often alongside counseling, and clinicians must weigh contraindications such as seizure disorder or eating disorders before prescribing. Because bupropion also treats depression, its use in this setting should be tied clearly to the substance treatment plan rather than a separate psychiatric indication to support accurate coding.
Coding & Documentation
A coder assigns this code when the record documents that a replacement medication was given to the patient specifically for addiction treatment, including the substance administered and the clinical setting. Supporting documentation typically includes the medication name, route, and confirmation that it was part of an addiction treatment protocol rather than treatment for an unrelated condition. A common mistake is using this code for medications given to manage withdrawal symptoms in a general medical or detox setting without a documented addiction treatment protocol, or failing to distinguish a one-time administration from an ongoing management encounter. Coders also sometimes overlook this code when it is bundled into a broader inpatient rehabilitation stay rather than billed as a discrete encounter.
Commonly Confused With
Pharmacotherapy is most often confused with Medication Management, since both involve replacement medications; the distinction is that Pharmacotherapy reflects the act of giving the medication, while Medication Management reflects clinical review and dose adjustment. It can also be confused with detoxification services, which focus on safely clearing a substance from the body rather than providing an ongoing replacement medication, and with general pharmacologic treatment codes used outside the substance abuse treatment section when the medication is not being used for addiction.